|
Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical |
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Honoraria - AstraZeneca; Lilly; Novartis; Ono Pharmaceutical; Shire; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha |
Consulting or Advisory Role - Shire |
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst) |
|
|
Honoraria - Amgen; Bayer; HalioDx; Merck Serono; Pierre Fabre; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Amgen; Baxalta; Bayer; HalioDx; Incyte; Merck Serono; MSD; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Roche; Sanofi |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical |
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Genentech/Roche; Target Pharmasolutions; Target Pharmasolutions (Inst) |
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst) |
|
|
Research Funding - Abbvie (Inst); Aminex (Inst); Bayer (Inst); BlueLink (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Samumed (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); TransThera Biosciences (Inst); XuanZhu (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Daiichi Sankyo; Epizyme; Lilly; Novartis; Roche |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche |
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche |
|
|
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; CareNet; Chugai Pharma; Clinical Trial Co; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Merck Sharp & Dohme; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Reno Medical; SymBio Pharmaceuticals; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation |
Speakers' Bureau - Astellas Pharma; Ono Pharmaceutical; Takeda |
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); Gritstone Bio (Inst); ICON Clinical Research (Inst); inVentiv Health (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Linical (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Quintiles Inc. (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Amgen; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Dompè; Ignyta; Incyte; Novartis; Octimet; Pfizer; Pierre Fabre; Roche; SERVIER |
Speakers' Bureau - Bristol-Myers Squibb; Menarini; MSD; Novartis; Pfizer; Roche |
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Roche |
|
|
Consulting or Advisory Role - Clovis Oncology |
Research Funding - , Boehringer Ingelheim (Inst); , Janssen Cilag, (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Roche |
|
|
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer |
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis |
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst) |
|
|
Employment - Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Daiichi Sankyo; Kyowa Hakko Kirin; MSD; Novartis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda |
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst) |